• Century Therapeutics posted a net loss of $21.65 million, or $0.11 per share, for the quarter ended March 31, 2026, swinging from net income of $76.56 million a year earlier.
• Operating loss widened to $23.68 million from operating income of $74.18 million in the prior-year quarter as collaboration revenue fell to no revenue from $109.16 million.
• R&D expense dropped 35.65% to $17.11 million on lower personnel and clinical trial spending; G&A expense decreased 21.75% to $6.58 million.
• Cash, cash equivalents, and marketable securities climbed to $217 million from $117.1 million at Dec. 31, 2025, extending cash runway into 1Q 2029.
• CNTY-813 remains on track for an IND in 4Q 2026 with initial clinical data expected in 2H 2027; CNTY-308 is still slated to enter the clinic in 2026, pending regulatory clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130800PRIMZONEFULLFEED9718593) on May 13, 2026, and is solely responsible for the information contained therein.